Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzastaurin in previously treated WM or MM
NCT00718419Phase 2
Key facts
- Status
- Completed
- Start
- Jul 2008
- Primary completion
- Sep 2010
- Countries
- 2
- Sponsor
- Eli Lilly and Company
- Modality
- Small Molecules
- Drugs
- enzastaurin
- Conditions
- Waldenstrom macroglobulinemia (WM)multiple myeloma (MM)
01
Overview
Phase 2, open-label, single-arm trial of enzastaurin in Waldenstrom macroglobulinemia (WM) and multiple myeloma (MM), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of Participants With Complete Response (CR), Partial Response (PR) and Minimal Response (MR) or Minor Response (MinR) up to 40.51 months. Started Jul 2008; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Enzastaurin
Single-agent Enzastaurin
03
Who it enrols
Patients with previously treated Waldenstrom's Macroglobulinemia or Multiple Myeloma (1-5 prior therapies) with adequate organ function and no prior allogeneic transplant.
04
Endpoints
Primary
Percentage of Participants With Complete Response (CR), Partial Response (PR) and Minimal Response (MR) or Minor Response (MinR)
Secondary
Duration of Response
Time to Progressive Disease
Number of Participants With Adverse Events
Beyond the preview
Go deeper on NCT00718419.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00718419.